[go: up one dir, main page]

AU2002229573A1 - Pharmaceutical formulation containing pyrazolo(4,3-D)pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives - Google Patents

Pharmaceutical formulation containing pyrazolo(4,3-D)pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives

Info

Publication number
AU2002229573A1
AU2002229573A1 AU2002229573A AU2957302A AU2002229573A1 AU 2002229573 A1 AU2002229573 A1 AU 2002229573A1 AU 2002229573 A AU2002229573 A AU 2002229573A AU 2957302 A AU2957302 A AU 2957302A AU 2002229573 A1 AU2002229573 A1 AU 2002229573A1
Authority
AU
Australia
Prior art keywords
prostaglandins
pyrimidines
antagonists
calcium
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002229573A
Inventor
Hans-Michael Eggenweiler
Volker Eiermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10063224A external-priority patent/DE10063224A1/en
Priority claimed from DE2000163882 external-priority patent/DE10063882A1/en
Priority claimed from DE2000164993 external-priority patent/DE10064993A1/en
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2002229573A1 publication Critical patent/AU2002229573A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002229573A 2000-12-19 2001-11-28 Pharmaceutical formulation containing pyrazolo(4,3-D)pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives Abandoned AU2002229573A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE10063224 2000-12-19
DE10063224A DE10063224A1 (en) 2000-12-19 2000-12-19 Drug formulation useful e.g. for treating angina or hypertension contains pyrazolo (4,3-d) pyrimidine derivative phosphodiesterase V inhibitor and antithrombotic agent, calcium antagonist or prostaglandin
DE2000163882 DE10063882A1 (en) 2000-12-21 2000-12-21 Drug formulation useful e.g. for treating angina or hypertension contains pyrazolo (4,3-d) pyrimidine derivative phosphodiesterase V inhibitor and antithrombotic agent, calcium antagonist or prostaglandin
DE10063882 2000-12-21
DE10064993 2000-12-23
DE2000164993 DE10064993A1 (en) 2000-12-23 2000-12-23 Drug formulation useful e.g. for treating angina or hypertension contains pyrazolo (4,3-d) pyrimidine derivative phosphodiesterase V inhibitor and antithrombotic agent, calcium antagonist or prostaglandin
PCT/EP2001/013916 WO2002049651A1 (en) 2000-12-19 2001-11-28 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives

Publications (1)

Publication Number Publication Date
AU2002229573A1 true AU2002229573A1 (en) 2002-07-01

Family

ID=27214208

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002229573A Abandoned AU2002229573A1 (en) 2000-12-19 2001-11-28 Pharmaceutical formulation containing pyrazolo(4,3-D)pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives

Country Status (16)

Country Link
US (1) US20040063730A1 (en)
EP (1) EP1343506A1 (en)
JP (1) JP2004516270A (en)
KR (1) KR20030059349A (en)
CN (1) CN1481244A (en)
AR (1) AR035676A1 (en)
AU (1) AU2002229573A1 (en)
BR (1) BR0115995A (en)
CA (1) CA2431077A1 (en)
CZ (1) CZ20031776A3 (en)
HU (1) HUP0303315A2 (en)
MX (1) MXPA03005393A (en)
NO (1) NO20032773L (en)
PL (1) PL362513A1 (en)
SK (1) SK8192003A3 (en)
WO (1) WO2002049651A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035531A1 (en) * 2001-01-22 2004-06-02 Novartis Ag COMPOSITION FOR THE CONTROL OF ENDOPARASITIC PESTS IN LIVESTOCK AND DOMESTIC ANIMALS, A METHOD FOR THEIR CONTROL AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF MEDICINES
DE60237425D1 (en) * 2002-03-28 2010-10-07 Univerzita Palackeho V Olomouc PyrazoloÄ4,3-diphyrimidines, process for their preparation and therapeutic use
DE10229778A1 (en) * 2002-07-03 2004-01-29 Bayer Ag New use of imidazotriazinones
FR2842809A1 (en) * 2002-07-26 2004-01-30 Greenpharma Sas NOVEL SUBSTITUTED PYRAZOLO [1,5-a] -1,3,5-TRIAZINES AND THEIR ANALOGUES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, USE AS A MEDICAMENT AND METHODS FOR THEIR PREPARATION
KR100468352B1 (en) * 2002-09-24 2005-01-27 한국과학기술연구원 New pyrazolopyrimidine derivatives, process for their preparation and pharmaceutical composition comprising the same
JP4015176B2 (en) 2003-04-29 2007-11-28 ファイザー・インク 5,7-Diaminopyrazolo 4,3-dipyrimidines useful for the treatment of hypertension
DK1628663T3 (en) * 2003-05-15 2010-03-08 Roskamp Res Llc Process for the preparation of medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
EP1742950B1 (en) * 2004-04-07 2008-12-17 Pfizer Limited Pyrazolo[4,3-d] pyrimidines
WO2008121386A2 (en) * 2007-03-30 2008-10-09 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
ES2449594T3 (en) * 2007-10-05 2014-03-20 Alzheimer's Institute Of America, Inc. Method to reduce amyloid deposition, amyloid neurotoxicity and microgliosis with enantiomer (-) - nilvadipine
US20100093810A1 (en) * 2007-10-05 2010-04-15 Alzheimer's Institute Of America, Inc. Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
KR101678699B1 (en) * 2008-08-13 2016-11-23 액테리온 파마슈티칼 리미티드 Therapeutic compositions containing macitentan
CN107106541A (en) * 2015-01-28 2017-08-29 瑞采生技有限公司 Compounds for enhancing PPAR γ expression and nuclear translocation and medical uses thereof
MA46191A (en) 2016-09-09 2021-04-21 Incyte Corp PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND THEIR USES FOR THE TREATMENT OF CANCER
TW201811799A (en) 2016-09-09 2018-04-01 美商英塞特公司 Pyrazolopyrimidine compounds and uses thereof
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
TWI778050B (en) 2017-04-21 2022-09-21 美商醫肯納腫瘤學公司 Indole ahr inhibitors and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
LT3755703T (en) 2018-02-20 2022-10-10 Incyte Corporation N-(PHENYL)-2-(PHENYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
ES2973117T3 (en) 2018-09-25 2024-06-18 Incyte Corp Pyrazolo[4,3-d]pyrimidine compounds as modulators of ALK2 and/or FGFR
CR20220097A (en) 2019-08-06 2022-06-01 Incyte Corp SOLID FORMS OF AN INHIBITOR OF HPK1
WO2021108528A1 (en) 2019-11-26 2021-06-03 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2353285A1 (en) * 1975-09-17 1977-12-30 Doms Laboratoires Coronary vasodilator controlled release dipyridamole compsn. - comprises film coated granules giving reduced side effects and also showing angina pectoris suppressing action
JPS5459266A (en) * 1977-10-14 1979-05-12 Ono Pharmaceut Co Ltd Prostaglandin i2 analogs and their preparation
FR2568774B2 (en) * 1984-05-30 1989-05-19 Choay Sa DRUGS THAT PROMOTE BLOOD FLOW PROPERTIES AND THEIR THERAPEUTIC USE
FR2672601B1 (en) * 1991-02-08 1994-10-14 Synthelabo BENZO-1,5-THIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
DE19709877A1 (en) * 1997-03-11 1998-09-17 Bayer Ag 1,5-dihydro-pyrazolo [3,4-d] pyrimidinone derivatives
JP2003525845A (en) * 1997-10-28 2003-09-02 ヴィヴァス・インコーポレイテッド Topical administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
DE19942474A1 (en) * 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo [4,3-d] pyrimidines
DE10058662A1 (en) * 2000-11-25 2002-05-29 Merck Patent Gmbh Use of pyrazolo [4,3-d] pyrimidines
DE10103647A1 (en) * 2001-01-27 2002-08-01 Merck Patent Gmbh Process for the preparation of a pyrazolo (4,3-d) pyrimidine derivative

Also Published As

Publication number Publication date
CN1481244A (en) 2004-03-10
NO20032773D0 (en) 2003-06-18
WO2002049651A1 (en) 2002-06-27
NO20032773L (en) 2003-06-18
HUP0303315A2 (en) 2004-01-28
SK8192003A3 (en) 2003-10-07
CZ20031776A3 (en) 2003-09-17
AR035676A1 (en) 2004-06-23
KR20030059349A (en) 2003-07-07
EP1343506A1 (en) 2003-09-17
PL362513A1 (en) 2004-11-02
US20040063730A1 (en) 2004-04-01
MXPA03005393A (en) 2003-09-25
BR0115995A (en) 2004-01-13
JP2004516270A (en) 2004-06-03
CA2431077A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
AU2002229573A1 (en) Pharmaceutical formulation containing pyrazolo(4,3-D)pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives
AU2001291893A1 (en) Use of substituted imidazo(1,2-a)pyridine-, imidazo(1,2-a)pyrimidine and imidazo(1,2-a)pyrazine-3-yl-amine derivatives for producing NOS-inhibiting medicaments
SI1220856T1 (en) Pyrazolo(4,3-d)pyrimidine derivatives
HUP0103472A3 (en) Pyrrolo[2,3-d]pyrimidine derivatives and pharmaceutical compositions containing the same
EP1416935B8 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
AU2927595A (en) Aqueous risperidone formulations
AU7727400A (en) Traction fluid formulation
HUP0301114A3 (en) Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them
AU7588696A (en) Pyrido{2, 3-D} pyrimidine derivatives and pharmaceutical compositions thereof
AU3854295A (en) Sustained release caffeine formulation
SI0891978T1 (en) 5H-Thiazolo (3,2-a) pyrimidine derivatives
AU2001292185A1 (en) Formulation containing amoxicillin
AU2001295657A1 (en) Formulation containing wax-esters
HUP0002902A3 (en) 3-substituted 3,4 dyhydro-thieno[2,3-d]pyrimidine derivatives and their use for the preparation of pharmaceutical compositions
AU2002361407A1 (en) Triazolo(4,3-a)pyrido(2,3-d)pyrimidin-5-one derivatives, compositions containing same, preparation method and use thereof
AU5491699A (en) Process for the preparation of pyrrolo(2,3-d)pyrimidines
AU4207197A (en) 3-substituted pyrido(4',3':4,5)thieno(2,3-d)pyrimidine derivatives, their preparation and their use
AU2002221853A1 (en) Oxabicyclo(2.2.1)heptane derivatives as pesticidal agents
DE50001191D1 (en) PYRAZOLO [4, 3-D] PYRIMIDINE
PL340734A1 (en) Fungicidal compositions containing derivatives of thiene [2.3-d] pyrimidin-4-one
AU2002215979A1 (en) Use of pyrazolo(4,3-D)pyrimidines
AU1223400A (en) Novel pterin antineoplastic agents
AU2002216033A1 (en) Use of pyrazolo(4,3-d)pyrimidines
HUP0002736A3 (en) 3-substituted pyrido [3',4':4,5]thieno[2,3-d]pyrimidine derivatives, and their use for the preparation of pharmaceutical compositions
AU2002226362A1 (en) Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)